EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma

British Journal of Cancer

Volumn 71, Issue 2, 1995, Pages 371-375

  De Mulder, P H M ^a   Oosterhof, G O N ^b   Bouffioux, C ^c   van Oosterom, A T ^d   Vermeylen, K ^e   Sylvester, R ^e  

^a Uniersity Hospital Nipmegen ^*  (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Universy of Liège ^*  (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e EORTC DATA CENTER   (Belgium)

Author keywords

Interferon alpha; Interferon gamma; Renal cell cio

Indexed keywords

IMMUNOSTIMULATING AGENT; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; KIDNEY CARCINOMA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

ADULT; AGED; BIOLOGICAL RESPONSE MODIFIERS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DRUG SYNERGISM; FEMALE; HUMANS; INTERFERON ALFA-2A; INTERFERON-GAMMA, RECOMBINANT; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0028798749     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.75     Document Type: Article

References (32)

1. AULITZKY W, GASTL WE, AULITZKY WE, HEROLD M, KEMMLER J, MULL B, FRICK J AND HUBER C, (1989). Successful treatment of metastatic renal cell carcinoma with a biological active dose of recombinant interferon-gamma. J, Clin. Oncol., 7, 1875-1884.
2. BRUNTSCH U, DE MULDER PHM, TEN BOKKEL HUININK WW, CLAVEL M, DROZD K, KAY SB, RENARD J AND VAN GLABBEKE M, (1990). Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma. J, Biol. Response Mod., 9, 335-338.
3. BUZAID AC AND TODD MB, (1989). Therapeutic options in renal cell carcinoma. Semin. Oncol., 16, 12-19.
4. CZARNIECKI CW, FENNIE CW, POWERS DB AND ESTELL DA, (1984). Synergistic antiviral and anti proliferative activities of E, coli derived human alpha, beta, and gamma interferon. J, Virol., 49, 490–496.
5. DE FORGES A, REY A, KLINK M, GHOSN M, KRAMAR A AND DROZ JP, (1988). Prognostic factors in adult metastatic renal carcinoma: a multivariate analysis. Semin. Surg. Oncol., 4, 149-154.
6. DE MULDER PHM, DEBRUYNE FMJ, FRANSSEN MPH, GEBROERS AD, STRIJK S, REINTJES AG, DOESBURG WH AND DAMSMA O, (1990). Phase I II study of recombinant interferon alpha and gamma in advanced progressive renal cell carcinoma. Cancer Immunol. Immunother., 31, 321-324.
7. DE MULDER PHM, FRANSSEN MPH, PUNT CJA AND DEBRUYNE FMJ, (1991). Monotherapy and combination therapy with interferon-alpha. interferon-gamma and tumor necrosis factoralpha in metastatic renal cell carcinoma. In Immunotherapy of Renal Cell Carcinoma, Clinical and Experimental Developments. Debruyne FMJ, Bukowski RM, Pontes JE AND De Mulder PHM (eds) pp. 82-90. Springer: Berlin.
8. ERNSTOFF MS, NAIR S, BAHNSON RR, MIKETIC LM, BANNER B, GOODING W, CAY R, WHITESIDE T, HAKALA T AND KIRKWOOD JM, (1990). A phase la trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon-gamma and recombinant interferon-alfa in patients with metastatic renal cell carcinoma. J, Clin. Oncol., 8, 1637-1649.
9. FOSSA SD, GUNDERSON R AND MOE B, (1990). Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate - a phase II study. Cancer. 65, 2451-2454.
10. FOON K, DOROSHOW J, BONNEM E, FEFER A, GRAHAM S, GROSH B, NARAYAN P., ELIAS L, HARVEY H AND SCHULOF R (1988). A prospective randomized trial of a2b-interferon y-interferon or the combination in advanced metastatic renal cell carcinoma. J, Biol. Response Mod., 7, 540–545.
11. GARNICK MB, REICH SD, MAXWELL B, COVAL-GOLDSMITH S, RITCHIE JP AND RUDNICK SA, (1988). Phase I II study of recombinant interferon gamma in advanced renal cell carcinoma. J, Urol., 139, 251-255.
12. GEBOERS ADH, DE MULDER PHM, DEBRUYNE FMJ, STRIJK SP AND DAMSMA O, (1988). Alpha and gamma interferon in the treatment of advanced renal cell carcinoma. Semin. Surg. Oncol., 4, 191-194.
13. GOLDSTEIN D AND LASLO J, (1986). Interferon therapy in cancer: from imaginon to interferon. Cancer Res., 46, 4315-4329.
14. GRANDER D, OBERG K, LUNDQVIST M, JANSON ET, ERIKSSON B AND EINHORN S, (1990). Interferon induced enhancement of 2’5'-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet. 36, 337–340.
15. HARRIS DT, (1983). Hormonal therapy and chemotherapy of renal cell carcinoma. Semin. Oncol., 10, 422-430.
16. HOROSZEWICZ S AND MURPHY GP, (1989). An assessment of the current use of human interferons in therapv of urological cancers. J, Urol., 142, 1173-1180.
17. HUBBELL HR, CRAFT JA, LEIBOWITZ PH AND GILLESPIE DH. (1987). Synergistic antiproliferative effect of recombinant alphainterferons with recombinant gamma-interferons. J, Biol. Response Mod., 6, 141-153.
18. KROWN SE, (1987). Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 59, 647-651.
19. KURZROCK R, ROSENBLUM MG, QUESADA JR, SHERWIN SA, ITRI LM AND GUTTERMAN JU, (1986). Phase I study of a recombinant interferon-alph and recombinant-gamma in cancer patients. J, Clin. Oncol., 4, 1677-1683.
20. MALUISH AE, URBA WJ, LONGO DL, OVERTON WR, COGGIN D, CRISP ER, WILLIAMS R, SHERWIN SA, GORDON J AND STEIS RG, (1988). The determination of an immunologically active dose of interferon gamma in patients with melanoma. J, Clin. Oncol., 6, 434–445.
21. McCUNE CS, (1983). Immunologic therapies in kidney carcinoma. Semin. Oncol., 10, 431-436.
22. MONTIE JE, STEWART BH, STRAFFON RA, BANOWSKY LH, HEWITT CB AND MONTAGUE DK, (1977). The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J, Urol., 117, 272-275.
23. MUSS HB, (1988). Interferon therapy of metastatic renal cell cancer. Semin. Surg. Oncol., 4, 199-203.
24. OTTO U, CONRAD S, SCHNEIDER AW AND KLOSTERHALFEN H. (1988). Recombinant interferon gamma in the treatment of metastatic renal cell carcinoma. Arzneim. Forsch. Drug Res., 38, 38. 1658.
25. QUESADA JR, KURZROCK R, SHERWIN SA AND GUTTERMAN JU, (1987). Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J, Biol. Response Mod., 6, 20-27.
26. QUESADA JR, EVANS L, SAKS SR AND GUTTERMAN JU (1988). Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma. J, Biol. Response Mod., 7, 234-239.
27. RINEHART JJ, MALSPEIS L, YOUNG D AND NEIDHART JA, (1986). Phase I II trial of human recombinant interferon gamma in renal cell carcinoma. J, Biol. Response Mod., 5, 300-308.
28. RITCHIE AWS AND CHRISHOLM GD, (1983). The natural history of renal cell carcinoma. Semin. Oncol., 10, 390-400.
29. SARNA G, FIGLIN R AND DEKERNION J. (1987). Interferon in renal cell carcinoma. The UCLA experience. Cancer, 59, 610-612.
30. VAN OOSTEROM AT, TANNOCK I, MATSUMURA Y, AKAZA H, EINSTEIN M, HAFERMANN M, HALL R, HIRAO Y, JONES W, KOONTZ W, MURPHY G, RAGHAVAN D, OGAWA M, SPLINTER T, STOTER G AND WAUSMAN Z. (1993). Response criteria in phase II/phase III studies of invasive bladder cancer. In Consensus Development in Clinical Bladder Cancer Research, Proceedings of the Second and Third International Consensus Development Symposia, Niijima T, Aso Y, Koontz W, Prout G AND Denis L, (eds) pp. 17-26 Brussels.
31. VEDANTHAM S, GAMLIEL H AND GOLOMB HM, (1992). Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. Cancer Res., 52, 1056-1066.
32. YAGODA A AND BANDER NH, (1989). Failure of cytotoxic chemotherapy, 1983-1988. and the emerging role of monoclonal antibodies for renal cancer. Urol. Int., 44, 338-345.